124341-06-6

Upstream product

• 76006-33-2 3-bromo-2-methylbenzoic acid 
• 106976-22-1 5-bromo-4-methylisatin 

Downstream Products

• 124341-07-7 2-(acetylamino)-5-bromo-6-methylbenzoic acid 
• 124340-69-8 5-Methyl-2-phenyl-1H-benzoimidazole-4-carboxylic acid (2-dimethylamino-ethyl)-amide 

Relevant academic research and scientific papers

QUINAZOLINEDIONES AS TANKYRASE INHIBITORS

This invention relates to the use of quinazolinediones for the modulation, notably the inhibition of the activity of tankyrases (TNKS1 and TNKS2). Suitably, the present invention relates to the use of quinazolinediones in the treatment of cancer, fibrosis and other hyperproliferative diseases through this mechanism.

2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS

A class of compounds for the treatment of viral infections. Compounds of particular interest are defined by Formula II STR1 wherein R 28 is selected from (a) amino substituted with one or two radicals selected from alkyl, aralkyl, heterocycoalkyl, heterocyclo, and aryl, and (b) amino acid residues and derivatives thereof; wherein R 29 is selected from hydrido, alkyl, halo, STR2 wherein R 30 is selected from alkyl, alkoxy, alkylamino, carboxyalkyl, alkoxyalkyl, alkylaminoalkyl, cycloalkyl, heterocyclo, heterocycloalkyl, heterocycloalkoxy, alkylaminoalkoxy, alkylaminoalkylamino, heterocycloalkylamino, and N-aralkylamino; wherein R 31 is alkyl; wherein R 32 is alkyl and aryl; or a pharmaceutically-acceptable salt thereof.

Potential Antitumor Agents. 59. Structure-Activity Relationships for 2-Phenylbenzimidazole-4-carboxamides, a New Class of "Minimal" DNA-Intercalating Agents Which May Not Act via Topoisomerase II

A series of substituted 2-phenylbenzimidazole-4-carboxamides has been synthesized and evaluated for in vitro and in vivo antitumor activity.These compounds represent the logical conclusion to our search for "minimal" DNA-intercalating agents with the lowest possible DNA-binding constants.Such "2-1" tricyclic chromophores, of lower aromaticity than the structurally similar 2-phenylquinolines, have the lowest DNA binding affinity yet seen in the broad series of tricyclic carboxamide intercalating agents.Despite very low in vitro cytotoxicities, several of the compoundshad moderate levels of in vivo antileukemic effects.However, the most interesting aspect of their biological activity was the lack of cross-resistance shown to an amsacrine-resistant P388 cell line, suggesting that these compounds may not express their cytotoxicity via interaction with topoisomerase II.